Positive Phase 1b results for ATX-304 suggest scientists may finally be able to restore a key metabolic pathway that declines with age.
There are few ideas in aging biology that have generated as much excitement (and as much disappointment) as AMPK.
Researchers have viewed this cellular pathway as one of the body’s most important regulators of metabolism. It helps cells decide when to store energy, when to use it and how to respond when fuel becomes scarce. As we age, AMPK activity gradually declines, taking with it some of the metabolic flexibility that helps keep us healthy.
Scientists have long suspected that restoring AMPK activity could improve metabolic health, potentially mimicking some of the benefits associated with exercise. The problem is that proving this in humans has proved remarkably difficult.
This week, Cambrian Bio reported what may be a significant breakthrough. At the American Diabetes Association’s 86th Scientific Sessions, the company presented positive Phase 1b data for ATX-304, an investigational drug designed to activate the broader AMPK network [1]. The results suggest that a mechanism many in the longevity field have pursued for years may finally be translating from theory into human biology.
Now, what happens when metabolism starts slowing down? Most people don’t wake up one morning and notice that their metabolism is aging; it’s gradual. Recovery after exercise takes longer. Maintaining muscle becomes more difficult. Extra weight seems easier to gain and harder to lose. Even people who remain active often find that their bodies no longer respond quite the way they did a decade earlier. Much of this change stems from declining metabolic efficiency inside our cells.
One way to think about AMPK is as a thermostat for cellular energy. When energy levels drop, AMPK helps coordinate the body’s response, directing cells to take in fuel and use it efficiently. Over time, that system becomes less responsive.
The result is not just weight gain. Metabolic decline is increasingly linked to a wide range of age-related conditions, from diabetes and fatty liver disease to cardiovascular dysfunction. That’s why researchers in the emerging field of geroscience have become so interested in AMPK – not simply as an obesity target, but as a potential lever for improving how we age.
The first signs that the biology works in humans
The Phase 1b trial enrolled 23 adults with obesity and prediabetes who received either ATX-304 or a placebo for eight weeks.
The study was not designed to produce dramatic weight loss. Instead, researchers wanted to answer a more fundamental question: could the drug successfully activate the metabolic processes that decades of laboratory research had predicted? The answer appears to be yes. Participants receiving ATX-304 showed significant improvements in several measures linked to metabolic health. Liver fat declined, visceral fat – the deeper fat surrounding internal organs – was reduced, and triglyceride levels improved.
Moreover, researchers observed a substantial increase in adiponectin, a hormone associated with healthy fat metabolism, alongside an 8% increase in resting metabolic rate. That means participants’ bodies appeared to be using more energy even while at rest.
Importantly, these changes occurred without the safety concerns that have historically complicated efforts to increase metabolism through drugs. Meanwhile, treatment-related side effects were largely mild and comparable to placebo, with no signs of metabolic overstimulation.
“The Phase 1b data for ATX-304 demonstrate statistically significant improvements across multiple metabolic parameters, including liver fat, visceral adipose tissue, triglycerides, adiponectin, and resting metabolic rate,” said Dr Ruth Thieroff-Ekerdt, Chief Medical Officer of Cambrian Bio.
She noted that researchers observed no adverse events related to core body temperature or heart rate, important markers when evaluating therapies designed to increase energy expenditure.
Beyond appetite suppression
The obesity field has been transformed by GLP-1 therapies, which primarily help people lose weight by reducing appetite and food intake. ATX-304 represents a very different philosophy. Rather than encouraging the body to consume less energy, the drug is designed to improve how energy is used.
Obesity and metabolic aging are not necessarily the same problem. Weight gain is one visible symptom of metabolic decline, but underlying changes in mitochondrial function, muscle performance and energy production often begin years earlier. Cambrian believes ATX-304 may eventually address those underlying processes.
“Unlocking the potential of AMPK activation has been a major drug development goal for almost 30 years, and for the first time, we have demonstrated activity of an AMPK activator in humans,” said Dr James Peyer, CEO and Founder of Cambrian Bio. “The full AMPK Network Activation of ATX-304 elevates overall metabolic activity in a cell, driving up both substrate availability and use, increasing energy expenditure in a manner that closely resembles aerobic exercise training.”
That comparison to exercise is likely to attract attention within longevity circles. Exercise remains the most consistently validated intervention for extending healthspan. Any therapy capable of reproducing even part of its biological effects would represent a meaningful advance.
The immediate commercial opportunity for ATX-304 lies in obesity and cardiometabolic disease, where demand for new therapies remains enormous, but the broader significance may lie elsewhere. One of the central ideas in longevity science is that aging itself can be approached through the biological systems that deteriorate over time. Metabolism is one of those systems. If researchers can safely restore metabolic function at the cellular level, they may be addressing a root cause rather than a downstream consequence.
That possibility remains speculative. The current study was small, and much larger trials will be needed before researchers know whether the observed improvements translate into meaningful long-term health outcomes. Still, the results are notable because they represent something the field has not seen before: evidence that a long-sought aging-related pathway can be successfully activated in humans.
Cambrian is now preparing two Phase 2 studies. REWIRE-1 will examine the effects of higher doses on muscle function and lipid metabolism, while REWIRE-2 will evaluate weight loss in people with obesity.
For now, the most important takeaway is not that ATX-304 increased metabolic rate or reduced liver fat. It is that one of longevity science’s most compelling theories may finally have crossed the divide between the laboratory and the clinic.
